List view / Grid view

Giacomo Chiesi (Executive Vice President Chiesi Global Rare Diseases)

 

news

New partnership targets CNS symptoms in ultra-rare diseases

Chiesi Group and Key2Brain have signed a global license agreement…

24 June 2025 | By

Chiesi Group and Key2Brain have signed a global license agreement to develop two blood-brain barrier-crossing enzyme replacement therapies for alpha-mannosidosis and Krabbe disease – with the aim to help patients with limited treatment options.